Ziemann, Adam et al "A Phase 1, Multiple-dose Study of Elezanumab (ABT-555) in Patients with Relapsing Forms of Multiple Sclerosis (S56.001)." Neurology 92.15 Supplement (2019): S56.001. Web. 05 May. 2021.